190 related articles for article (PubMed ID: 34821148)
1. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test.
Ibrahim SF; Kasprzak JM; Hall MA; Fitzgerald AL; Siegel JJ; Kurley SJ; Covington KR; Goldberg MS; Farberg AS; Trotter SC; Reed K; Brodland DG; Koyfman SA; Somani AK; Arron ST; Wysong A
Future Oncol; 2022 Mar; 18(7):833-847. PubMed ID: 34821148
[TBL] [Abstract][Full Text] [Related]
2. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma.
Wysong A; Newman JG; Covington KR; Kurley SJ; Ibrahim SF; Farberg AS; Bar A; Cleaver NJ; Somani AK; Panther D; Brodland DG; Zitelli J; Toyohara J; Maher IA; Xia Y; Bibee K; Griego R; Rigel DS; Meldi Plasseraud K; Estrada S; Sholl LM; Johnson C; Cook RW; Schmults CD; Arron ST
J Am Acad Dermatol; 2021 Feb; 84(2):361-369. PubMed ID: 32344066
[TBL] [Abstract][Full Text] [Related]
3. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.
Litchman GH; Fitzgerald AL; Kurley SJ; Cook RW; Rigel DS
Curr Med Res Opin; 2020 Aug; 36(8):1295-1300. PubMed ID: 32372702
[No Abstract] [Full Text] [Related]
4. Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
Wysong A; Somani AK; Ibrahim SF; Cañueto J; Fitzgerald AL; Siegel JJ; Prasai A; Goldberg MS; Farberg AS; Regula C; Bar A; Kasprzak J; Brodland DG; Koyfman SA; Arron ST
Dermatol Ther (Heidelb); 2024 Mar; 14(3):593-612. PubMed ID: 38424384
[TBL] [Abstract][Full Text] [Related]
5. Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
Hooper PB; Farberg AS; Fitzgerald AL; Siegel JJ; Rackley BB; Prasai A; Kurley SJ; Goldberg MS; Litchman GH
Cancer Invest; 2022 Nov; 40(10):911-922. PubMed ID: 36073945
[TBL] [Abstract][Full Text] [Related]
6. Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management.
Farberg AS; Hall MA; Douglas L; Covington KR; Kurley SJ; Cook RW; Dinehart SM
Curr Med Res Opin; 2020 Aug; 36(8):1301-1307. PubMed ID: 32351136
[No Abstract] [Full Text] [Related]
7. Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma.
Arron ST; Wysong A; Hall MA; Bailey CN; Covington KR; Kurley SJ; Goldberg MS; Kasprzak JM; Somani AK; Ibrahim SF; Brodland DG; Cleaver NJ; Maher IA; Xia Y; Koyfman SA; Newman JG
Laryngoscope Investig Otolaryngol; 2022 Feb; 7(1):135-144. PubMed ID: 35155791
[TBL] [Abstract][Full Text] [Related]
8. Analytical validity of DecisionDx-SCC, a gene expression profile test to identify risk of metastasis in cutaneous squamous cell carcinoma (SCC) patients.
Borman S; Wilkinson J; Meldi-Sholl L; Johnson C; Carter K; Covington KR; Fitzgerald AL; Kurley SJ; Farberg AS; Goldberg MS; Monzon FA; Oelschlager K; Cook RW
Diagn Pathol; 2022 Feb; 17(1):32. PubMed ID: 35216597
[TBL] [Abstract][Full Text] [Related]
9. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.
Gastman BR; Gerami P; Kurley SJ; Cook RW; Leachman S; Vetto JT
J Am Acad Dermatol; 2019 Jan; 80(1):149-157.e4. PubMed ID: 30081113
[TBL] [Abstract][Full Text] [Related]
10. The Prognostic Value and Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test in Cutaneous Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.
Masarwy R; Shilo S; Carmel Neiderman NN; Kampel L; Horowitz G; Muhanna N; Mansour J
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173922
[TBL] [Abstract][Full Text] [Related]
11. Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists.
Rebeca T; Giselle P; Litchman GH; Rigel DS
J Drugs Dermatol; 2019 Oct; 18(10):980-984. PubMed ID: 31584775
[TBL] [Abstract][Full Text] [Related]
12. Incorporation of the 40-Gene Expression Profile (40-GEP) Test to Improve Treatment Decisions in High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients: Case Series and Algorithm.
Singh G; Tolkachjov SN; Farberg AS
Clin Cosmet Investig Dermatol; 2023; 16():925-935. PubMed ID: 37051586
[TBL] [Abstract][Full Text] [Related]
13. Association of a 40-Gene Expression Profile With Risk of Metastatic Disease Progression of Cutaneous Squamous Cell Carcinoma (cSCC) and Specification of Benefit of Adjuvant Radiation Therapy.
Arron ST; Cañueto J; Siegel J; Fitzgerald A; Prasai A; Koyfman SA; Yom SS
Int J Radiat Oncol Biol Phys; 2024 May; ():. PubMed ID: 38810706
[TBL] [Abstract][Full Text] [Related]
14. Estimation of Prognosis in Invasive Cutaneous Melanoma: An Independent Study of the Accuracy of a Gene Expression Profile Test.
Greenhaw BN; Zitelli JA; Brodland DG
Dermatol Surg; 2018 Dec; 44(12):1494-1500. PubMed ID: 29994951
[TBL] [Abstract][Full Text] [Related]
15. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
[TBL] [Abstract][Full Text] [Related]
16. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test for Improved Patient Management Decisions and Disease-Related Outcomes when Combined with Current Clinicopathological Risk Factors for Cutaneous Squamous Cell Carcinoma (cSCC): Case Series.
Au JH; Hooper PB; Fitzgerald AL; Somani AK
Dermatol Ther (Heidelb); 2022 Feb; 12(2):591-597. PubMed ID: 34951694
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a nomogram incorporating gene expression profiling and clinical factors for accurate prediction of metastasis in patients with cutaneous melanoma following Mohs micrographic surgery.
Thorpe RB; Covington KR; Caruso HG; Quick AP; Zolochevska O; Bricca GM; Campoli M; DeBloom JR; Fazio MJ; Greenhaw BN; Kirkland EB; Machan ML; Brodland DG; Zitelli JA
J Am Acad Dermatol; 2022 Apr; 86(4):846-853. PubMed ID: 34808324
[TBL] [Abstract][Full Text] [Related]
19. Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.
Greenhaw BN; Covington KR; Kurley SJ; Yeniay Y; Cao NA; Plasseraud KM; Cook RW; Hsueh EC; Gastman BR; Wei ML
J Am Acad Dermatol; 2020 Sep; 83(3):745-753. PubMed ID: 32229276
[TBL] [Abstract][Full Text] [Related]
20. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
